公开(公告)号：WO2017019175A1

公开(公告)日：2017-02-02

申请号：PCT/US2016/035391

申请日：2016-06-02

Applicant: NEWLINK GENETICS CORPORATION

Inventor： MAUTINO, Mario ,  KUMAR, Sanjeev ,  JAIPURI, Firoz ,  WALDO, Jesse ,  POTTURI, Hima ,  ZHUANG, Hong

IPC: A61K31/405 ,  A61K31/198 ,  A61K31/661

CPC classification number: C07D209/20 ,  A61K31/285 ,  C07C309/04 ,  C07C309/20 ,  C07D401/12 ,  C07D405/12 ,  C07F9/65742

Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

Abstract translation: 目前提供的是吲哚美多前药和盐化合物和药物组合物，其包含吲哚美辛盐的盐和前药，其与需要治疗由吲哚胺-23介导的免疫抑制的患者相比，产生增强的血浆浓度和暴露于吲哚美德与直接给予吲哚并肟 - 加氧酶途径，如患有癌症或慢性传染病的患者。